A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
They play a crucial role in countless bodily functions, from managing inflammation to triggering tissue repair
The compound is not scheduled under the Controlled Substances Act and is not explicitly banned but it also lacks FDA approval and has no place on the 503A Bulk Drug Substances List, which is the only pathway for licensed compounding pharmacies to legally dispense it
While these peptides are popular in muscle-related research discussions, outcomes depend on study design, dosage parameters, and biological variables
Independent Verification Third-party testing ensures unbiased analysis, free from internal influence or conflicts of interest
Well, injecting into the belly area is a simple and basically painless procedure, so it isnt much to worry about in that regard
